mDETECT
- Diagnostics
The rapidly growing number of cancer drugs on the market warrants comparable patient monitoring tools that can determine cancer progression and scope of drug efficacy, especially in the late stages of cancer (i.e., metastatic stage). For these patients, there is an urgent clinical need to have better tools to monitor their cancer and response to therapy. Our sequencing based blood test allows for rapid assessment of treatment response as an early determination of treatment efficacy, and therefore allows for a timely change in treatment leading to longer and better lives for these patients. Our tests are highly sensitive, IP protected, high throughput, automated, cost effective - all of which have led to securing a global commercial partner. We have a launch date for our first product in market by Jan 2026.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}